J. Safra Sarasin Holding AG grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 26.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,041 shares of the medical device company’s stock after buying an additional 9,758 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $2,891,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in DXCM. Brighton Jones LLC raised its position in DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Empowered Funds LLC raised its holdings in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth lifted its position in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Robert W. Baird set a $80.00 target price on DexCom in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.88.
DexCom Price Performance
Shares of DXCM stock opened at $76.35 on Tuesday. The company has a market capitalization of $29.46 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.23 and a beta of 1.45. The company’s 50-day simple moving average is $69.95 and its two-hundred day simple moving average is $68.51. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was up 15.0% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.
Insiders Place Their Bets
In other news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $72.00, for a total value of $1,926,432.00. Following the completion of the sale, the insider owned 355,726 shares of the company’s stock, valued at $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,450 shares of company stock worth $5,270,409. 0.28% of the stock is owned by company insiders.
DexCom Company Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Stories
- Five stocks we like better than DexCom
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
